BACKGROUND: While immediate benefits of levodopa-carbidopa intestinal gel (LCIG) are evident in patients with Parkinson's disease (PD), long-term LCIG effects require further study. OBJECTIVES: We explored long-term LCIG on motor symptoms, nonmotor symptoms (NMS), and LCIG treatment settings in patients with advanced PD (APD). METHODS: Data were obtained (medical records and patient visit) from COSMOS, a multinational, retrospective, cross-sectional post-marketing observational study in patients with APD. Patients were stratified into 5 groups based on LCIG treatment duration at the patient visit, from 1-2 to > 5 years LCIG. Between-group differences were assessed for changes from baseline in LCIG settings, motor symptoms, NMS, add-on medications, and safety. RESULTS: Out of 387 patients, the number of patients per LCIG group was: > 1- ≤ 2 years LCIG (n = 156); > 2- ≤ 3 years LCIG (n = 80); > 3- ≤ 4 years LCIG (n = 61); > 4- ≤ 5 years LCIG (n = 30); > 5 years LCIG (n = 60). Baseline values were similar; data reported are changes from the baseline. There were reductions in "off" time, dyskinesia duration, and severity across LCIG groups. Prevalence, severity, and frequency of many individual motor symptoms and some NMS were reduced amongst all LCIG groups, with few differences between groups. Doses for LCIG, LEDD and LEDD for add-on medications were similar across groups both at LCIG initiation and patient visit. Adverse events were similar across all LCIG groups and consistent with the established safety profile of LCIG. CONCLUSIONS: LCIG may provide sustained, long-term symptom control, while potentially avoiding increases in add-on medication dosages. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03362879. Number and date: P16-831, November 30, 2017.

AbbVie Inc North Chicago IL USA

Department of Neurology and Center of Clinical Neurosciences 1st Faculty of Medicine Charles University Prague and General University Hospital Prague Prague Czech Republic

Edmond J Safra Program in Parkinson's Disease and the Morton and Gloria Shulman Movement Disorders Clinic Toronto Western Hospital UHN Division of Neurology University of Toronto Toronto ON Canada

Krembil Research Institute Toronto ON Canada

Movement Disorders Unit Neurological Institute Tel Aviv Medical Center Tel Aviv University Tel Aviv Yafo Israel

Movement Disorders Unit San Carlos Clinical Hospital Complutense University of Madrid Madrid Spain

Victor Babes University of Medicine and Pharmacy Timisoara Romania

Zobrazit více v PubMed

Hauser RA. Levodopa: past, present, and future. Eur Neurol. 2009;62:1–8. doi: 10.1159/000215875. PubMed DOI

Antonini A, Poewe W, Chaudhuri KR, Jech R, Pickut B, Pirtosek Z, Szasz J, Valldeoriola F, Winkler C, Bergmann L, Yegin A, Onuk K, Barch D, Odin P, co-investigators Gs Levodopa–carbidopa intestinal gel in advanced Parkinson's: final results of the GLORIA registry. Parkinsonism Relat Disord. 2017;45:13–20. doi: 10.1016/j.parkreldis.2017.09.018. PubMed DOI

Brooks DJ. Optimizing levodopa therapy for Parkinson's disease with levodopa/carbidopa/entacapone: implications from a clinical and patient perspective. Neuropsychiatr Dis Treat. 2008;4:39–47. doi: 10.2147/NDT.S1660. PubMed DOI PMC

Wang L, Li J, Chen J. Levodopa–carbidopa intestinal gel in Parkinson's disease: a systematic review and meta-analysis. Front Neurol. 2018;9:620. doi: 10.3389/fneur.2018.00620. PubMed DOI PMC

Contin M, Riva R, Albani F, Baruzzi A. Pharmacokinetic optimisation in the treatment of Parkinson's disease. Clin Pharmacokinet. 1996;30:463–481. doi: 10.2165/00003088-199630060-00004. PubMed DOI

Jourdain VA, Tang CC, Holtbernd F, Dresel C, Choi YY, Ma Y, Dhawan V, Eidelberg D. Flow-metabolism dissociation in the pathogenesis of levodopa-induced dyskinesia. JCI Insight. 2016;1:e86615. doi: 10.1172/jci.insight.86615. PubMed DOI PMC

Tambasco N, Romoli M, Calabresi P. Levodopa in Parkinson's disease: current status and future developments. Curr Neuropharmacol. 2018;16:1239–1252. doi: 10.2174/1570159X15666170510143821. PubMed DOI PMC

Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord. 2001;16:448–458. doi: 10.1002/mds.1090. PubMed DOI

Fahn S. Parkinson disease, the effect of levodopa, and the ELLDOPA trial. Earlier vs Later L-DOPA. Arch Neurol. 1999;56:529–535. doi: 10.1001/archneur.56.5.529. PubMed DOI

Hardoff R, Sula M, Tamir A, Soil A, Front A, Badarna S, Honigman S, Giladi N. Gastric emptying time and gastric motility in patients with Parkinson's disease. Mov Disord. 2001;16:1041–1047. doi: 10.1002/mds.1203. PubMed DOI

Kurlan R, Rothfield KP, Woodward WR, Nutt JG, Miller C, Lichter D, Shoulson I. Erratic gastric emptying of levodopa may cause "random" fluctuations of parkinsonian mobility. Neurology. 1988;38:419–421. doi: 10.1212/WNL.38.3.419. PubMed DOI

van Wamelen DJ, Grigoriou S, Chaudhuri KR, Odin P. Continuous drug delivery aiming continuous dopaminergic stimulation in Parkinson's disease. J Parkinsons Dis. 2018;8:S65–S72. doi: 10.3233/JPD-181476. PubMed DOI PMC

Martinez-Martin P, Rodriguez-Blazquez C, Kurtis MM, Chaudhuri KR, Group NV. The impact of non-motor symptoms on health-related quality of life of patients with Parkinson's disease. Mov Disord. 2011;26:399–406. doi: 10.1002/mds.23462. PubMed DOI

Hayes MT. Parkinson's disease and Parkinsonism. Am J Med. 2019;132:802–807. doi: 10.1016/j.amjmed.2019.03.001. PubMed DOI

Song Z, Zhang J, Xue T, Yang Y, Wu D, Chen Z, You W, Wang Z. Different catechol-o-methyl transferase inhibitors in Parkinson's disease: a bayesian network meta-analysis. Front Neurol. 2021;12:707723. doi: 10.3389/fneur.2021.707723. PubMed DOI PMC

Davis KL, Edin HM, Allen JK. Prevalence and cost of medication nonadherence in Parkinson's disease: evidence from administrative claims data. Mov Disord. 2010;25:474–480. doi: 10.1002/mds.22999. PubMed DOI

Wimmer BC, Bell JS, Fastbom J, Wiese MD, Johnell K. Medication regimen complexity and polypharmacy as factors associated with all-cause mortality in older people: a population-based cohort study. Ann Pharmacother. 2016;50:89–95. doi: 10.1177/1060028015621071. PubMed DOI PMC

Choi J, Horner KA (2022) Dopamine agonists. In: StatPearls. Treasure Island

Haasio K. Toxicology and safety of COMT inhibitors. Int Rev Neurobiol. 2010;95:163–189. doi: 10.1016/B978-0-12-381326-8.00007-7. PubMed DOI

Feldmann F, Zipprich HM, Witte OW, Prell T. Self-reported nonadherence predicts changes of medication after discharge from hospital in people with Parkinson's disease. Parkinsons Dis. 2020;2020:4315489. PubMed PMC

Mendorf S, Witte OW, Grosskreutz J, Zipprich HM, Prell T. What predicts different kinds of nonadherent behavior in elderly people with Parkinson's disease? Front Med (Lausanne) 2020;7:103. doi: 10.3389/fmed.2020.00103. PubMed DOI PMC

Mendorf S, Witte OW, Zipprich H, Prell T. Association between nonmotor symptoms and nonadherence to medication in Parkinson's disease. Front Neurol. 2020;11:551696. doi: 10.3389/fneur.2020.551696. PubMed DOI PMC

Cereda E, Cilia R, Klersy C, Canesi M, Zecchinelli AL, Mariani CB, Tesei S, Sacilotto G, Meucci N, Zini M, Isaias IU, Cassani E, Goldwurm S, Barichella M, Pezzoli G. Swallowing disturbances in Parkinson's disease: a multivariate analysis of contributing factors. Parkinsonism Relat Disord. 2014;20:1382–1387. doi: 10.1016/j.parkreldis.2014.09.031. PubMed DOI

Daley DJ, Myint PK, Gray RJ, Deane KH. Systematic review on factors associated with medication non-adherence in Parkinson's disease. Parkinsonism Relat Disord. 2012;18:1053–1061. doi: 10.1016/j.parkreldis.2012.09.004. PubMed DOI

Kruger R, Lingor P, Doskas T, Henselmans JML, Danielsen EH, de Fabregues O, Stefani A, Sensken SC, Parra JC, Onuk K, Yegin A, Antonini A. An observational study of the effect of levodopa–carbidopa intestinal gel on activities of daily living and quality of life in advanced Parkinson's disease patients. Adv Ther. 2017;34:1741–1752. doi: 10.1007/s12325-017-0571-2. PubMed DOI PMC

Standaert DG, Rodriguez RL, Slevin JT, Lobatz M, Eaton S, Chatamra K, Facheris MF, Hall C, Sail K, Jalundhwala YJ, Benesh J. Effect of levodopa–carbidopa intestinal gel on non-motor symptoms in patients with advanced Parkinson's disease. Mov Disord Clin Pract. 2017;4:829–837. doi: 10.1002/mdc3.12526. PubMed DOI PMC

Fabbri M, Zibetti M, Calandra-Buonaura G, Contin M, Sambati L, Mohamed S, Romagnolo A, Berchialla P, Imbalzano G, Giannini G, Rizzone MG, Artusi CA, Cortelli P, Lopiano L. Levodopa/carbidopa intestinal gel long-term outcome in Parkinson's disease: focus on dyskinesia. Mov Disord Clin Pract. 2020;7:930–939. doi: 10.1002/mdc3.13068. PubMed DOI PMC

Fernandez HH, Standaert DG, Hauser RA, Lang AE, Fung VS, Klostermann F, Lew MF, Odin P, Steiger M, Yakupov EZ, Chouinard S, Suchowersky O, Dubow J, Hall CM, Chatamra K, Robieson WZ, Benesh JA, Espay AJ. Levodopa–carbidopa intestinal gel in advanced Parkinson's disease: final 12-month, open-label results. Mov Disord. 2015;30:500–509. doi: 10.1002/mds.26123. PubMed DOI PMC

Olanow CW, Kieburtz K, Odin P, Espay AJ, Standaert DG, Fernandez HH, Vanagunas A, Othman AA, Widnell KL, Robieson WZ, Pritchett Y, Chatamra K, Benesh J, Lenz RA, Antonini A, Group LHS. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol. 2014;13:141–149. doi: 10.1016/S1474-4422(13)70293-X. PubMed DOI PMC

Slevin JT, Fernandez HH, Zadikoff C, Hall C, Eaton S, Dubow J, Chatamra K, Benesh J. Long-term safety and maintenance of efficacy of levodopa–carbidopa intestinal gel: an open-label extension of the double-blind pivotal study in advanced Parkinson's disease patients. J Parkinsons Dis. 2015;5:165–174. doi: 10.3233/JPD-140456. PubMed DOI

Wirdefeldt K, Odin P, Nyholm D. Levodopa–carbidopa intestinal gel in patients with Parkinson's disease: a systematic review. CNS Drugs. 2016;30:381–404. doi: 10.1007/s40263-016-0336-5. PubMed DOI

Nyholm D, Nilsson Remahl AI, Dizdar N, Constantinescu R, Holmberg B, Jansson R, Aquilonius SM, Askmark H. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease. Neurology. 2005;64:216–223. doi: 10.1212/01.WNL.0000149637.70961.4C. PubMed DOI

Antonini A, Pahwa R, Odin P, Isaacson SH, Merola A, Wang L, Kandukuri PL, Alobaidi A, Yan CH, Bao Y, Zadikoff C, Parra JC, Bergmann L, Chaudhuri KR. Comparative effectiveness of device-aided therapies on quality of life and off-time in advanced Parkinson's Disease: a systematic review and Bayesian Network meta-analysis. CNS Drugs. 2022;36:1269–1283. doi: 10.1007/s40263-022-00963-9. PubMed DOI PMC

Nijhuis FAP, Esselink R, de Bie RMA, Groenewoud H, Bloem BR, Post B, Meinders MJ. Translating evidence to advanced parkinson's disease patients: a systematic review and meta-analysis. Mov Disord. 2021;36:1293–1307. doi: 10.1002/mds.28599. PubMed DOI PMC

Liu XD, Bao Y, Liu GJ. Comparison between levodopa–carbidopa intestinal gel infusion and subthalamic nucleus deep-brain stimulation for advanced Parkinson's disease: a systematic review and meta-analysis. Front Neurol. 2019;10:934. doi: 10.3389/fneur.2019.00934. PubMed DOI PMC

Chaudhuri KR, Pickard AS, Alobaidi A, Jalundhwala YJ, Kandukuri PL, Bao Y, Sus J, Jones G, Ridley C, Oddsdottir J, Najle-Rahim S, Madin-Warburton M, Xu W, Schrag A. The cost effectiveness of levodopa–carbidopa intestinal gel in the treatment of advanced Parkinson's disease in England. Pharmacoeconomics. 2022;40:559–574. doi: 10.1007/s40273-022-01132-y. PubMed DOI PMC

Aldred J, Anca-Herschkovitsch M, Antonini A, Bajenaru O, Bergmann L, Bourgeois P, Cubo E, Davis TL, Iansek R, Kovacs N, Kukreja P, Onuk K, Pontieri FE, Robieson W, Siddiqui MS, Simu M, Standaert DG, Chaudhuri KR. Application of the '5-2-1' screening criteria in advanced Parkinson's disease: interim analysis of DUOGLOBE. Neurodegener Dis Manag. 2020;10:309–323. doi: 10.2217/nmt-2020-0021. PubMed DOI

Poewe W, Bergmann L, Kukreja P, Robieson WZ, Antonini A. Levodopa–carbidopa intestinal gel monotherapy: GLORIA registry demographics, efficacy, and safety. J Parkinsons Dis. 2019;9:531–541. doi: 10.3233/JPD-191605. PubMed DOI PMC

Chaudhuri KR, Kovács N, Pontieri F, Aldred J, Bourgeois P, Davis T, Cubo E, Anca-Herschkovitsch M, Iansek R, Siddiqui M, Simu M, Bergmann L, Kukreja P, Ladhani O, Jia J, Standaert D (2022) P1.272 long-term motor and non-motor symptom benefits in patients with advanced Parkinson’s disease treated with levodopa–carbidopa intestinal gel: final analysis of the 36-month DUOGLOBE real-world multinational observational study. In: American Academy of Neurology. Seattle, Washington, USA

De Fabregues O, Dot J, Abu-Suboh M, Hernandez-Vara J, Ferre A, Romero O, Ibarria M, Seoane JL, Raguer N, Puiggros C, Gomez MR, Quintana M, Armengol JR, Alvarez-Sabin J. Long-term safety and effectiveness of levodopa–carbidopa intestinal gel infusion. Brain Behav. 2017;7:e00758. doi: 10.1002/brb3.758. PubMed DOI PMC

Fasano A, Gurevich T, Jech R, Kovacs N, Svenningsson P, Szasz J, Parra JC, Bergmann L, Johnson A, Sanchez-Solino O, Tang Z, Vela-Desojo L. Concomitant medication usage with levodopa–carbidopa intestinal gel: results from the COSMOS study. Mov Disord. 2021;36:1853–1862. doi: 10.1002/mds.28596. PubMed DOI PMC

Parkinson's Disease Composite scale. https://www.epda.eu.com/get-involved/the-parkinsons-disease-composite-scale/#:~:text=Developed%20by%20the%20My%20PD,with%20Parkinson's%20in%20a%20timely, Accessed 5 Oct 2022.

Deuschl G, Antonini A, Costa J, Smilowska K, Berg D, Corvol JC, Fabbrini G, Ferreira J, Foltynie T, Mir P, Schrag A, Seppi K, Taba P, Ruzicka E, Selikhova M, Henschke N, Villanueva G, Moro E. European academy of neurology/movement disorder society-European section guideline on the treatment of Parkinson's disease: I. Invasive therapies. Mov Disord. 2022;37:1360–1374. doi: 10.1002/mds.29066. PubMed DOI

Burack M, Aldred J, Zadikoff C, Vanagunas A, Klos K, Bilir B, Fernandez HH, Standaert DG. Implementing levodopa–carbidopa intestinal gel for Parkinson disease: insights from US Practitioners. Mov Disord Clin Pract. 2018;5:383–393. doi: 10.1002/mdc3.12630. PubMed DOI PMC

Catalan MJ, Antonini A, Calopa M, Bajenaru O, de Fabregues O, Minguez-Castellanos A, Odin P, Garcia-Moreno JM, Pedersen SW, Pirtosek Z, Kulisevsky J. Can suitable candidates for levodopa/carbidopa intestinal gel therapy be identified using current evidence? eNeurol Sci. 2017;8:44–53. PubMed PMC

Merola A, Romagnolo A, Zibetti M, Bernardini A, Cocito D, Lopiano L. Peripheral neuropathy associated with levodopa–carbidopa intestinal infusion: a long-term prospective assessment. Eur J Neurol. 2016;23:501–509. doi: 10.1111/ene.12846. PubMed DOI

Pauls KAM, Toppila J, Koivu M, Eerola-Rautio J, Udd M, Pekkonen E. Polyneuropathy monitoring in Parkinson's disease patients treated with levodopa/carbidopa intestinal gel. Brain Behav. 2021;11:e2408. doi: 10.1002/brb3.2408. PubMed DOI PMC

Kovács N, Szasz J, Vela-Desojo L, Svenningsson P, Femia S, Parra JC, Sanchez-Solino O, Bergmann L, Gurevich T, Fasano A. Motor and nonmotor symptoms in patients treated with 24-hour daily levodopa–carbidopa intestinal gel infusion: analysis of the COmedication Study assessing Mono- and cOmbination therapy with levodopa–carbidopa inteStinal gel (COSMOS) Parkinsonism Relat Disord. 2022;105:139–144. doi: 10.1016/j.parkreldis.2022.08.002. PubMed DOI

Zobrazit více v PubMed

ClinicalTrials.gov
NCT03362879